Yahoo
NYSE - Nasdaq Real Time Price USD

Teleflex Incorporated (TFX)

138.98 -0.02 (-0.01%)
At close: October 28 at 4:00:02 PM EDT
140.51 +1.62 (+1.17%)
Pre-Market: 7:51:29 AM EDT
Trade TFX on Coinbase
Chart Range Bar
Loading chart for TFX

What's happening with TFX?

33m ago
Powered by Yahoo Scout

Teleflex received FDA Breakthrough Device Designation for its Freesolve resorbable magnesium scaffold, supporting its interventional cardiology strategy. The device remains investigational in the United States, while Teleflex continues restructuring, debt reduction, and product-integration efforts. The next major company event is its third-quarter 2026 update scheduled for November 5.

Powered by Yahoo Scout
  • Previous Close 139.00
  • Open 138.03
  • Bid --
  • Ask --
  • Day's Range 136.92 - 140.17
  • 52 Week Range 100.18 - 145.00
  • Volume 630,141
  • Avg. Volume 712,010
  • Market Cap (intraday) 5.889B
  • Beta (5Y Monthly) 0.83
  • PE Ratio (TTM) --
  • EPS (TTM) -8.48
  • Earnings Date Nov 5, 2026
  • Forward Dividend & Yield 1.36 (0.98%)
  • 1y Target Est 154.00
  • Zacks Rating Neutral

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications in the United States, Europe, the Middle East, Africa, the Asia Pacific, and internationally. The company offers vascular and emergency medicine products comprising Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous bone access systems for the administration of intravenous therapies, measurement of blood pressure, and collection of blood samples; intraosseous access systems consisting of EZ-IO intraosseous vascular access systems, and Arrow FAST1 sternal intraosseous infusion systems; and hemostatic products, including external hemostats and trauma products under the QuikClot brand. It also provides interventional products, including various coronary catheters, structural heart support devices, and peripheral intervention products platforms; GuideLiner, Turnpike, and TrapLiner catheters; MANTA vascular closure devices and Arrow OnControl powered bone biopsy systems; and coronary and peripheral medical devices, such as drug-coated balloons, stents, and balloon catheters. In addition, the company offers surgical products, including metal and polymer ligating clips using manual and automatic applier system, fascial closure surgical systems used in laparoscopic surgical procedures, percutaneous surgical systems, powered bariatric staplers, and other surgical instruments under the Weck, MiniLap, Pleur-Evac, Deknatel, KMedic, Pilling, and Titan SGS brands. It serves hospitals, healthcare providers, and medical device manufacturers. The company also sells its products online. Teleflex Incorporated was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.

www.teleflex.com

15,500

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 10/28/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

TFX
14.79%
S&P 500 (^GSPC)
13.13%

1-Year Return

TFX
7.62%
S&P 500 (^GSPC)
12.38%

3-Year Return

TFX
20.40%
S&P 500 (^GSPC)
88.08%

5-Year Return

TFX
58.46%
S&P 500 (^GSPC)
68.48%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue 570.33M
Earnings 99.69M
Profit Margin 17.48%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

-500M
0
500M
-100.0%
-50.0%
0.0%

Analyst Insights

View More

Analyst Price Targets

138.00
154.00 Average
138.98 Current
170.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 10/14/2026
Analyst Truist Securities
Rating Action Maintains
Rating Hold
Price Action Lowers
Price Target 150 -> 142

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -45.76%

  • Return on Assets (ttm)

    1.75%

  • Return on Equity (ttm)

    -0.70%

  • Revenue (ttm)

    2.25B

  • Net Income Avi to Common (ttm)

    -25.05M

  • Diluted EPS (ttm)

    -8.48

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    323.94M

  • Total Debt/Equity (mrq)

    101.10%

  • Levered Free Cash Flow (ttm)

    179.54M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: